SCHEMBL474153

SCHEMBL474153

C[N]S(=O)(=O)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.52
HSD17B10 Q99714 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
KDM4E B2RXH2 3/20 0.52
MAPT P10636 2/20 0.52
LMNA P02545 1/20 0.52
HTR6 P50406 2/20 0.50
PSIP1 O75475 1/20 0.48
KMT2A Q03164 4/20 0.47
DDAH1 O94760 1/20 0.47
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA3 P07451 1/20 0.46
CA4 P22748 1/20 0.46
CA6 P23280 1/20 0.46
CA5A P35218 1/20 0.46
CA7 P43166 1/20 0.46
PLA2G7 Q13093 1/20 0.46
CA9 Q16790 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL544207 0.78 HTR6 (0.55) ALDH1A1HSD17B10TDP1KDM4EMAPT
SCHEMBL127246 0.77 F2 (0.57) ALDH1A1LMNAKMT2ACA12CA1
SCHEMBL18025296 0.77 ALDH1A1 (0.50) ALDH1A1HSD17B10TDP1KDM4EMAPT
SCHEMBL6172350 0.76 HTR6 (0.52) ALDH1A1HSD17B10TDP1KDM4EMAPT
SCHEMBL3520533 0.76 CA1 (0.55) ALDH1A1HSD17B10TDP1KDM4EMAPT
SCHEMBL6363790 0.75 ALDH1A1 (0.57) ALDH1A1HSD17B10KDM4EMAPTKMT2A
SCHEMBL5441568 0.75 ALDH1A1 (0.48) ALDH1A1HSD17B10TDP1KDM4EMAPT
SCHEMBL7301352 0.75 F2 (0.55) ALDH1A1TDP1MAPTCA12CA1
SCHEMBL7303158 0.75 F2 (0.55) ALDH1A1KMT2ACA1CA2TSHR
SCHEMBL5234947 0.75 KMT2A (0.35) ALDH1A1MAPTLMNAKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708344-B2 Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease HOFFMANN-LA ROCHE INC. (US) 2023-07-25 US claimed
US-20230074887-A1 FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE HOFFMANN-LA ROCHE INC. (US) 2023-03-09 US claimed
CN-113754541-A Micromolecule inhibitor targeting EB virus nuclear antigen protein, preparation method and application thereof 深圳湾实验室 2021-12-07 CN claimed
EP-3860984-A1 FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE F. Hoffmann-La Roche AG (CH) 2021-08-11 EP claimed
CN-112912371-A Flavone derivatives for treating and preventing hepatitis B virus diseases 豪夫迈·罗氏有限公司 2021-06-04 CN claimed
CN-107033157-B Bisbenzylisoquinoline derivative and application thereof in preparing medicament for treating or preventing tumor 贵州省中国科学院天然产物化学重点实验室 2020-05-05 CN claimed
WO-2020070088-A1 FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2020-04-09 WO claimed
US-10189812-B2 Bi-benzyl isoquinoline derivative, preparation method and use thereof in hepatopathy treatment and prevention THE KEY LABORATORY OF CHEMISTRY FOR NATURAL PRODUC (CN) 2019-01-29 US claimed
US-20170260161-A1 BI-BENZYL ISOQUINOLINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF IN HEPATOPATHY TREATMENT AND PREVENTION VERSITECH LIMITED (CN) 2017-09-14 US claimed
US-8440830-B2 Tetrahydro-fused pyridines as histone deacetylase inhibitors 4SC AG (DE) 2013-05-14 US claimed
EP-0089004-A1 Process for dyeing fibrous material from natural polyamides CIBA-GEIGY AG (CH) 1983-09-21 EP claimed
US-4400317-A NO NEED TO PRECIPITATE PRODUCT FROM REACTION SOLUTION AMERICAN HOECHST CORPORATION (US) 1983-08-23 US claimed
EP-0062607-A2 Monoazo dyestuffs, their praparation and their use CIBA-GEIGY AG (CH) 1982-10-13 EP claimed
EP-0042357-A2 Azo dyes, their preparation and use CIBA-GEIGY AG (CH) 1981-12-23 EP claimed
US-4260540-A SPIN DYEING POLYACRYLONITRILE BAYER AKTIENGESELLSCHAFT (DE) 1981-04-07 US claimed
US-4225489-A Heterocyclic azo dyes and pigments containing 4-quinazolinone moieties BAYER AKTIENGESELLSCHAFT (DE) 1980-09-30 US claimed
US-4008211-A Betainic azo dyestuffs containing cobalt in complex union with a colorless, tridentate ligand CIBA-GEIGY AG (CH) 1977-02-15 US claimed
US-3980673-A INSECTICIDES, ACARICIDES BAYER AKTIENGESELLSCHAFT (DT) 1976-09-14 US claimed
US-3966704-A Naphthylazo naphthyl copper complex dyestuffs HOECHST AKTIENGESELLSCHAFT (DT) 1976-06-29 US claimed
US-3933785-A Azo compounds CIBA-GEIGY AG (CH) 1976-01-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170260161-A1 BI-BENZYL ISOQUINOLINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF IN HEPATOPATHY TREATMENT AND PREVENTION SLC10A1, SLC10A2, CYP4B1 ALDH1A1 1187/4885HSD17B10 720/4885TDP1 3632/4885
US-11708344-B2 Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease CCNE2, CCNE1, CCNT1 ALDH1A1 455/4885HSD17B10 902/4885TDP1 3220/4885
US-20230074887-A1 FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE CCNE2, CCNE1, CCNT1 ALDH1A1 455/4885HSD17B10 902/4885TDP1 3220/4885
US-10189812-B2 Bi-benzyl isoquinoline derivative, preparation method and use thereof in hepatopathy treatment and prevention SLC10A1, SLC10A2, CYP4B1 ALDH1A1 1187/4885HSD17B10 720/4885TDP1 3632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.